Osmetech launches new genetic test

The CYP2C9 gene is important in its involvement in the metabolism of 10% of all drugs, including non-steroidal anti-inflammatory drugs (eg celecoxib, ibuprofen), anti-coagulants (eg warfarin), anti-epileptic agents (eg phenytoin), cholesterol-lowering drugs (statins / eg fluvastatin) and anti-diabetic agents (eg aprepitant).

CYP2C9 polymorphisms result in a decrease or loss of enzyme activity, which can influence the appropriate dosage of the prescribed drug. The CYP2C9 test is important in optimizing the dosage of drugs or the selection of alternative drugs. Moreover, during the development of new drugs metabolized by CYP2C9, genetic tests assist in the appropriate selection of patients for clinical trials and the optimization of dosage for those patients based on their ability to metabolize the drug, the company said.

The CYP2C9 test will be available for research use only on the eSensor XT-8 System targeting the demand for such a test from pharmaceutical testing laboratories. The company has said that it may also seek the FDA approval for a CYP2C9 test.

James White, CEO of Osmetech, said: “We are delighted to have launched our second personalized medicine assay on the eSensor XT-8 System ahead of schedule. This is an exciting time for Osmetech as we commercialize and strengthen our pipeline of assays for our recently launched eSensor XT-8 System.”